Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $6.75 Consensus PT from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $11.80.

CMPX has been the topic of a number of analyst reports. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, November 11th. D. Boral Capital initiated coverage on shares of Compass Therapeutics in a research note on Monday. They issued a “buy” rating and a $32.00 price target for the company. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently modified their holdings of CMPX. Rovin Capital UT ADV bought a new position in shares of Compass Therapeutics during the third quarter worth approximately $25,000. Intech Investment Management LLC acquired a new position in Compass Therapeutics in the 3rd quarter valued at $30,000. XTX Topco Ltd bought a new position in Compass Therapeutics during the 3rd quarter worth $37,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics during the second quarter worth $41,000. Finally, Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics in the second quarter valued at about $68,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Trading Down 0.7 %

Compass Therapeutics stock opened at $1.50 on Monday. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The company has a fifty day simple moving average of $1.62 and a 200 day simple moving average of $1.42. The company has a market cap of $206.38 million, a P/E ratio of -4.05 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, equities research analysts forecast that Compass Therapeutics will post -0.35 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.